HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries

Marseille, Elliot; Dandona, Lalit; Marshall, Nell; Gaist, Paul; Bautista-Arredondo, Sergio; Rollins, Brandi; Bertozzi, Stefano M.; Coovadia, Jerry; Saba, Joseph; Lioznov, Dmitry; Jo-Ann Du Plessis; Krupitsky, Evgeny; Stanley, Nicci; Over, Mead; Peryshkina, Alena; Kumar, S.G. Prem; Muyingo, Sowedi; Pitter, Christian; Lundberg, Mattias; Kahn, James G.
January 2007
BMC Health Services Research;2007, Vol. 7, p108
Academic Journal
Background: Economic theory and limited empirical data suggest that costs per unit of HIV prevention program output (unit costs) will initially decrease as small programs expand. Unit costs may then reach a nadir and start to increase if expansion continues beyond the economically optimal size. Information on the relationship between scale and unit costs is critical to project the cost of global HIV prevention efforts and to allocate prevention resources efficiently. Methods: The "Prevent AIDS: Network for Cost- Effectiveness Analysis" (PANCEA) project collected 2003 and 2004 cost and output data from 206 HIV prevention programs of six types in five countries. The association between scale and efficiency for each intervention type was examined for each country. Our team characterized the direction, shape, and strength of this association by fitting bivariate regression lines to scatter plots of output levels and unit costs. We chose the regression forms with the highest explanatory power (R2). Results: Efficiency increased with scale, across all countries and interventions. This association varied within intervention and within country, in terms of the range in scale and efficiency, the best fitting regression form, and the slope of the regression. The fraction of variation in efficiency explained by scale ranged from 26% - 96%. Doubling in scale resulted in reductions in unit costs averaging 34.2% (ranging from 2.4% to 58.0%). Two regression trends, in India, suggested an inflection point beyond which unit costs increased. Conclusion: Unit costs decrease with scale across a wide range of service types and volumes. These country and intervention-specific findings can inform projections of the global cost of scaling up HIV prevention efforts.


Related Articles

  • Ethical Challenges In Long-Term Funding For HIV/AIDS. Brock, Dan W.; Wikler, Daniel // Health Affairs;Nov/Dec2009, Vol. 28 Issue 6, p1666 

    The global response to the AIDS pandemic aims for universal access to treatment and for pursuing every possible avenue to prevention. Skeptics, doubting that the huge increases in current funding levels needed for universal treatment will ever happen, would scale back antiretroviral treatment in...

  • Gonorrhoea control programme in the US proved cost effective.  // PharmacoEconomics & Outcomes News;12/2/2006, Issue 517, p7 

    The article discusses research being done on federally-funded efforts to control gonorrhea rates in the U.S. from 1971-2003. It references a study by H. W. Chesson in the October 2006 issue of "Sexually Transmitted Diseases." Information is presented on the estimated number of gonorrhea cases...

  • Clopidogrel worthwhile secondary prevention for vascular events.  // PharmacoEconomics & Outcomes News;3/26/2005, Issue 474, p14 

    Discusses research being done on the cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in Great Britain. Reference to a study by J. Karnon, A. Brennan et al, published in the January 2005 issue of the "Current Medical Research and Opinion" journal;...

  • Universal mass hepatitis A vaccination worthwhile in Chile.  // PharmacoEconomics & Outcomes News;9/10/2005, Issue 486, p5 

    Discusses research being done on the cost-effectiveness of universal childhood hepatitis A vaccination in Chile by M. T. Valenzuela, R. J. Jacobs, O. Arteaga, M. S. Navarrete, A. S. Meyerhoff and B. L. Innis, published in the July 14, 2005 issue of "Vaccine." Mathematical model used in...

  • The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India. Kazemian, Pooyan; Costantini, Sydney; Kumarasamy, Nagalingeswaran; Paltiel, A David; Mayer, Kenneth H; Chandhiok, Nomita; Walensky, Rochelle P; Freedberg, Kenneth A // Clinical Infectious Diseases;2/15/2020, Vol. 70 Issue 4, p633 

    Background The human immunodeficiency virus (HIV) epidemic in India is concentrated among 3.1 million men who have sex with men (MSM) and 1.1 million people who inject drugs (PWID), with a mean incidence of 0.9–1.4 per 100 person-years. We examined the cost-effectiveness of both...

  • Resource allocation within the National AIDS Control Program of Pakistan: a qualitative assessment of decision maker's opinions. Sara Husain; Masood Kadir; Zafar Fatmi // BMC Health Services Research;2007, Vol. 7, p11 

    Background: Limited resources, whether public or private, demand prioritisation among competing needs to maximise productivity. With a substantial increase in the number of reported HIV cases, little work has been done to understand how resources have been distributed and what factors may have...

  • Outputs, cost and efficiency of public sector centres for prevention of mother to child transmission of HIV in Andhra Pradesh, India. Dandona, Lalit; Prem Kumar, S. G.; Ramesh, Y. K.; Rao, M. Chalapathi; Marseille, Elliot; Kahn, James G.; Dandona, Rakhi // BMC Health Services Research;2008, Vol. 8, Special section p1 

    Background: Prevention of mother to child transmission (PMTCT) is an important part of the effort to control HIV. PMTCT services are mostly provided at public sector government hospitals in India. Systematic data on the cost and efficiency of providing PMTCT services in India are not available...

  • Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis. Miller, Mark A.; Shahab, Cathryn K. // PharmacoEconomics;2005, Vol. 23 Issue 4, p333 

    Outbreaks of meningococcal disease have caused devastation worldwide. Effective vaccines have not been used routinely, due to perceived limitations of the duration of effectiveness as well as immunogenicity when administered during infancy. Given the sporadic nature of outbreaks, the optimal use...

  • Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium. Annemans, Lieven; Rémy, Vanessa; Oyee, James; Largeron, Nathalie // PharmacoEconomics;2009, Vol. 27 Issue 3, p231 

    Background: The introduction of a quadrivalent human papillomavirus (HPV; types 6, 11, 16, 18) vaccine is expected to significantly reduce the burden of cervical cancer, cervical intraepithelial neoplasia (CIN), genital warts and other HPV-related diseases. Objective: To determine the cost...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics